Group 4A: HER2+ Breast Cancer; HR+ Breast Cancer; QOL & Survivorship

Poster #P3-02-02: Real-world time-to-treatment discontinuation in hormone-receptor-positive metastatic breast cancer patients following CDK4/6 inhibitor treatment, based on observational data collected through patient-partnered research

Poster #P4-01-37: Discontinuation of HER2+ targeted therapy among cancer survivors with metastatic HER2+ breast cancer: A case report

Sold out!

Waiting List

You're the first user in the Waiting List.

Date

Dec 15 2022

Time

10:00 am - 11:30 am

Zoom Webinar

Category
REGISTER